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A B S T R A C T 
Eczema or atopic dermatitis is a common childhood 
atopic disease associated with chronicity and 
impaired quality of life. As there is no cure 
for the disease, treatment relies on topical and 
systemic anti-allergic or immunomodulating 
therapies. Topical cortico-steroid, macrolide 
immunosuppressants, and oral immunomodulating 
drugs for recalcitrant disease have been the mainstay 
of therapy. Management of atopic dermatitis must 
consider the individual symptomatic variability of 
the disease. Basic therapy is focused on patient/
family education, hydrating topical treatment, 
and avoidance of specific and non-specific 
provocative factors. Anti-inflammatory treatment 
based on topical glucocorticosteroids and topical 
calcineurin inhibitors is used for exacerbation 
management and more recently in selective cases 
for proactive therapy. Systemic immunosuppressive 
treatment is an option for severe refractory cases. 
Microbial colonisation and superinfection may 
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Introduction
Eczema or atopic dermatitis (AD) is a chronically 
relapsing dermatosis that affects 9% to 20% of 
children in the US and is more prevalent in children 
who belong to upper socio-economic classes, 
smaller family sizes, and families with overzealous 
hygiene.1-7 The disease affects 5.6% of young children 
and 3.8% of school children and adolescents in Hong 
Kong.8,9 
 Children with AD may suffer from lack of 
sleep, irritability, daytime tiredness, emotional 
stress, lowered self-esteem, and psychological 
disturbance.10,11 The disruption of school, family 
life, and social interactions can severely impair the 
quality of life and extends beyond childhood. Parents 
may experience guilt, frustration, resentment, 
exhaustion, and helplessness due to their child’s 
condition.12 
 The diagnosis of AD is predominantly clinical, 
based on a constellation of clinical features. Firm 
criteria to define AD were first established by Hanifin 
and Rajka.2,13 The UK working diagnostic criteria are 
also concise and practical.14
 Atopic dermatitis involves defective cell-
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mediated immunity related to an imbalance in two 
subsets of CD4-T cells that creates a predominance 
of T-memory cells in the T-helper 2 pathways 
and preferential apoptosis of interferon-gamma 
producing T-helper 1 memory and effector T-
cells.15,16 Recently, we demonstrated that AD also 
involves many cellular and humoral immune 
mediators in addition to an aberration of cell-
mediated immunity.17
 There is a strong genetic predisposition. It has 
been shown that loss-of-function mutations in the 
filaggrin (filament-aggregating protein) [FLG] gene 
predispose to AD.18-22 Recent findings have shown 
that the affected skin of atopic individuals is deficient 
in filaggrin degradation products.23,24
 In summary, AD is an atopic/allergic 
disease that involves complex interactions among 
susceptible genes, immunological factors, skin 
barrier defects, infections, neuroendocrine factors, 
and environmental factors.2 Using clinical guidelines 
primarily but not exclusively from Europe, the US, 
Australia, Canada, Hong Kong, Korea and Japan, this 
paper summarises the contemporary therapeutics in 
management of childhood AD.
Review ARticleCME
induce disease exacerbation and justify additional 
antimicrobial treatment. Adjuvant therapy includes 
ultraviolet (UV) irradiation preferably with UVA1 
or narrowband UVB. Dietary recommendations 
should be specific and given only when food allergy 
is confirmed. Allergen-specific immunotherapy 
against aeroallergens may be useful in selected cases. 
Parallel use of traditional and proprietary topical and 
herbal medicine has also been popular in China and 
many cities in Asia. Complementary and alternative 
medicine may have a place but evidence-based data 
are lacking.
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治療兒童濕疹：臨床試驗得出甚麼結論？
梁銀河、韓錦倫
濕疹或遺傳過敏性皮膚炎是兒童常見的過敏性皮膚病，這種慢性病嚴
重影響他們的生活質素。由於濕疹不能治癒，舒緩的方法一般會依賴
局部或全身性抗過敏或免疫調節療法。一直以來，濕疹的主要方法為
外用皮質類固醇激素、免疫抑製劑大環內酯類，以及在頑固性病例使
用口服免疫調節藥物。治理方案必須因應患者個別情況而決定。基本
療法強調對患者和家人的教育、外用保濕治療，以及避免特殊性和非
特殊性的誘發因素。近年研究在合適病例施以外用糖皮質激素及外用
鈣調神經磷酸酶抑製劑的抗炎藥物可作積極長效治療，以控制病情。
全身性免疫抑制治療是針對嚴重難治性病例的其中一種方法。感染可
能誘發濕疹發作，此時必須加入抗菌藥物治療。輔助療法包括紫外線
照射，其中首選為UvA1或窄頻UvB。在確認食物過敏為濕疹發作的
誘因後，才向患者作出具體的飲食建議。一些對吸入過敏原產生過敏
的患者，針對性的減敏治療可能有用。在中國和其他許多亞洲地區，
同時使用傳統的和專有的中成藥治濕疹已經很流行。另類及替代醫學
療法可能有用，可惜缺乏實證醫學的數據支持。
Overview of atopic dermatitis 
therapeutic guidelines
Reviews and guidelines on management of AD have 
been published by various professional organisations 
worldwide.25-37 Most of the guidelines have provided 
recommendations for both children and adults 
while the National Institute for Health and Care 
Excellence (NICE) Guidelines focus on management 
of AD for children of 12 years and younger.36,38 These 
evidence-based guidelines are regularly reviewed 
and updated. The NICE guidelines were reviewed 
in 2011 and 2014 with no new recommendations or 
changes. The American Academy of Dermatology 
first published the guidelines in 2004 and recently 
updated them in 2014 with a more comprehensive 
review that was divided into four sections with 
paediatric considerations highlighted in the section 
on management and treatment with phototherapy 
and systemic agents.29-33,39 The new European 
Guidelines published in 201227,28 evaluated existing 
evidence-based guidelines from Germany, the 
Health Technology Assessment Report, and the 
position statement of the European Task Force 
on Atopic Dermatitis26 together with an appraisal 
of updated literature to provide consensus 
recommendations for management. In 2013, the 
Hong Kong College of Paediatricians formed a panel 
group with paediatricians and dermatologists to 
agree on management guidelines of AD in children 
based on the NICE guidelines for children with 
recommendations for local practice.40 
Overview of individual treatment
Emollient
Although emollients are widely recommended as 
the foundation in management of AD, their use is 
supported by only limited evidence.41-45 There is 
no evidence to show that any emollient is superior 
to their counterparts. A small-scale randomised 
controlled trial (RCT) showed that over-the-counter 
petroleum-based skin protectant moisturiser for 
mild-to-moderate AD in children has similar clinical 
efficacy and much higher cost-efficacy than the 
glycyrrhetinic acid–containing barrier repair cream 
or a ceramide-dominant barrier repair cream.46 
Recently concern has been raised about the possible 
adverse effects of sodium lauryl sulphate (SLS), a 
surfactant commonly found in many emollients 
like aqueous cream and emulsifying ointments. 
Aqueous cream has been shown to cause skin 
irritation, thinning of the cornea stratum, and 
increased transepidermal water loss following twice 
daily application for a few weeks.47-49 Hence, SLS-
containing emollients are more suitable as a soap 
substitute rather than left-on emollients. There is 
a lack of evidence for other bathing practices like 
addition of emollients to bathing water, while use 
of emollients immediately after bathing as ‘soak and 
seal’ can help maintain hydration.30,45 Generally, 
liberal use of emollients is recommended but it is 
uncertain whether their use in between periods of 
eczema flare-up helps to prevent further deterior-
ation and how different methods and timing of 
application of emollients influence their efficacy. 
 The Barrier Enhancement for Eczema 
Prevention research study (http://beepstudy.org) 
aims to find out whether skin care advice including 
application of emollients can prevent eczema in 
newborns. A pilot study identified 124 infants 
with high-risk factors for AD including more than 
one first-degree relative with a history of asthma, 
hay fever, or AD.50 Subjects were randomised to 
receive once-daily application of an emollient 
before the age of 3 weeks and continuing for 6 
months. The 6-month cumulative incidence of 
investigator-diagnosed eczema was 22% in the daily 
emollient group compared with 43% in controls 
corresponding to a relative risk reduction of 50%.50 
Another prospective RCT to investigate whether 
protecting the skin barrier with a moisturiser during 
the neonatal period could prevent development 
of AD and allergic sensitisation showed that daily 
application of moisturiser during the first 32 weeks 
of life reduces the risk of AD/eczema in infants.51 
These reports suggest that use of emollients might 
prevent development of AD in high-risk patients. 
Topical corticosteroids
Evidence for the use of topical corticosteroids (TCS) 
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in the management of AD is well established.52 
Topical corticosteroids are recommended as first-
line anti-inflammatory therapy for AD in children 
and adults.27,30,35,40 The TCS are classified in order of 
relative potency according to their vasoconstrictive 
effect.30,40 Different formulations of the same agent 
affect the potency, with ointment, cream, and lotion 
in descending order of clinical efficacy. There are 
limited clinical studies to compare the different 
types of TCS and evidence for recommendations 
on dosage, frequency, and duration of application is 
sparse. The choice of type and formulation of TCS 
depends on a number of factors including severity 
and site of lesions, patient’s age and preference. The 
NICE guidelines for children recommend use of the 
corresponding potency of TCS for severity of atopic 
eczema; mild potency for the face and neck and 
moderate potency only for short- term (3-5 days) use 
in severe flares; moderate or potent preparations for 
short periods only (7-14 days) for flares in vulnerable 
sites such as axillae and groin.36,53 Potent fluorinated 
corticosteroids should be avoided for infants and 
sensitive skin areas.34 Systematic reviews of studies 
that compared the frequency of application of 
newer-generation moderately potent to very potent 
steroids identified no benefit in outcome for more 
frequent applications over once-daily application.54 
In general, TCS should be applied once daily and 
no more than twice daily.36,38,53 During acute flares, 
it is advisable to use the strength and potency of 
steroids appropriate to the severity of the eczema 
daily to gain rapid control of inflammation, reducing 
gradually with a less-potent steroid or less-frequent 
application. 
 Topical corticosteroids are generally safe with 
few serious reported adverse effects.55,56 Risks of 
side-effects increase with higher potency, occlusion, 
thinner skin areas, severity of AD, young age, 
and longer duration of use. Local adverse effects 
include skin atrophy, telangiectasia, hypertrichosis, 
and striae.56 Skin absorption of TCS sufficient to 
cause clinical significant systemic adverse effects 
are rare. A systematic review of small-scale studies 
on the effects of hypothalamic-pituitary-adrenal 
(HPA) axis in children using TCS showed an overall 
good safety profile with a few cases demonstrating 
HPA suppression associated with use of potent 
TCS. Reports on effects of growth delay were 
inconclusive.57 Clinical monitoring of potential side-
effects of TCS is sufficient and routine monitoring 
of systemic side-effects is not recommended. Steroid 
phobia is a common cause of failure of treatment.58,59 
Parental concerns should be addressed to ensure 
adherence to treatment.60 Systematic review of seven 
case-control and cohort studies on pregnant women 
using TCS did not demonstrate an association of TCS 
with congenital abnormality or adverse outcome of 
pregnancy.61
Wet-wrap
Use of wet-wrap treatment was first described 
in detail in the early 1990s. Wet-wrap treatment 
involved application of TCS, with or without 
dilution, and emollients under layers of wet 
dressings. The principles of action included increase 
in TCS effects under occlusion, maintenance of skin 
hydration, cooling of inflamed skin, and reduction 
of scratching.62 Devillers and Oranje63 reviewed 
10 small-scale studies with two RCTs and eight 
observation studies of wet-wrap treatment in children 
with moderate-to-severe eczema. All except one 
study applied undiluted mild TCS (hydrocortisone) 
or diluted mild-to-potent steroid (1:5 to 1:50 
dilution) cream or ointment under two layers (one 
wet layer and one dry layer) of tubular bandages, 
maintained for 3 to 24 hours a day for a period of 2 to 
14 days. There were variations in the type of steroid, 
emollient, and dressing used for wet-wrap, but all 
studies reported improvement in eczema scores.63 
One study used emollients combined with 0.5% 
chlorhexidine and also showed mild improvement in 
SCORAD (SCORing Atopic Dermatitis) score after 
3 days of treatment. A recent RCT showed that wet-
wrap with diluted 1% mometasone ointment had 
a better outcome and acted faster than emollients 
only.64 The most common reported adverse effects 
include discomfort, mostly due to chills, and 
folliculitis more commonly caused by ointment. Six 
out of the 10 studies reported a temporary decrease 
in early morning serum cortisol that normalised 
afterwards.63 Most experts recommended wet-wrap 
with diluted steroids as a short-term second-line 
treatment for severe eczema after infection was 
controlled. A set of practice guidelines on wet-
wrap treatment was published by the same group of 
authors with a detailed description of methodology 
and materials used.62 Nonetheless climacteric and 
personal issues limit the usefulness of wet-wrap 
treatment outside of the hospital setting.65
Topical immunomodulants
Topical calcineurin inhibitors (TCI) are ascomycin 
macrolactam derivatives produced by Streptomyces 
strains of bacterium. Topical calcineurin inhibitors 
act through inhibition of calcineurin function and 
hence reduce the production and release of pro-
inflammatory cytokines in AD. Pimecrolimus cream 
1% and tacrolimus ointment 0.03% are licensed 
for use in patients older than 2 years. Tacrolimus 
ointment (0.1%) is recommended for use only 
over the age of 15 years and it remains part of the 
current recommendations by the US Food and Drug 
Administration (FDA).66-69 Short-term (3-12 weeks) 
and long-term (up to 1 year) studies of both TCIs 
showed that TCIs were significantly more effective 
than vehicle.40-42 Tacrolimus studies included 
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mostly patients with moderate-to-severe AD and 
pimecrolimus studies focused on mild-to-moderate 
AD.66-68 There is strong evidence that TCIs have a 
steroid-sparing effect and long-term use of up to 
12 months can prevent flares.66 Topical calcineurin 
inhibitors are particularly useful for sensitive 
sites including the face, neck, and skin flexures. 
Tacrolimus has been objectively shown to reduce 
itch and ameliorate sleep disturbance.70
 Three studies that directly compared the 
efficacy of pimecrolimus and tacrolimus involved 
mainly children with mild-to-severe AD and 
showed that tacrolimus was more effective than 
pimecrolimus.66,68 In comparing TCI and TCS, a few 
short-term paediatric studies showed that 0.03% and 
0.1% tacrolimus ointment was more effective than 
1% hydrocortisone acetate cream or ointment.66,68 
Two paediatric studies showed that 1% pimecrolimus 
is more effective than 1% hydrocortisone acetate 
and 0.1% triamcinolone acetate.68 One adult study 
showed that pimecrolimus was less effective than 
moderate TCS.67
 In long-term studies of children and adults, 
TCIs were well tolerated. The most common side-
effects were local irritation, erythema, or pruritus.66 
There was no evidence of increase in skin infections 
or skin atrophy even when TCIs were applied under 
occlusion. Systemic absorption was low and serum 
level did not accumulate following application for 
up to 12 months. Nonetheless data from animal 
studies on the risks of cancer associated with TCIs 
and post-marketing reports of lymphoma and skin 
cancer led the US FDA to issue recommendations 
for TCIs as short-term non-continuous therapy of 
AD in non-immunocompromised patients aged 2 
years or above,69 and approved a black-box warning 
label for the two TCIs pimecrolimus cream (1%) 
and tacrolimus ointment (0.03% and 0.1%) in 2006.66 
Subsequently, the efficacy and safety of TCIs have 
been systematically reviewed by various authors 
and professional groups: most concluded that 
TCIs are safe without evidence of increased risk 
of malignancy.55,66,69,71,72 At the moment, data from 
available human case-control and cohort studies 
have identified no causal association of TCIs with 
malignancies although the long-term potential 
carcinogenic risks of TCIs remain uncertain. Most 
international guidelines recommend that clinicians 
alert patients/parents to the black-box warning before 
starting treatment.26,30,36 The latest guidelines of the 
American Academy of Dermatology recommend 
off-label use of 0.03% tacrolimus ointment and 1% 
pimecrolimus for patients younger than 2 years with 
mild-to-severe AD.30
 
Proactive approach with topical  
anti-inflammatory therapy
Atopic dermatitis is a chronic relapsing inflammatory 
condition. Use of topical anti-inflammatory 
medications (TCS or TCI) intermittently only 
during acute flares and maintenance therapy with 
emollients during periods of clinical remission has 
been a common treatment strategy. Nonetheless, 
visually normal skin may have subclinical 
inflammation and be prone to exacerbations. There 
has been a paradigm shift in the approach to prevent 
flares through low-dose topical maintenance and 
proactive therapy after stabilisation of an acute 
exacerbation.32,73 A systematic review identified 
eight RCTs of proactive treatment with four trials 
of tacrolimus, three trials of fluticasone propionate, 
and one of methylprednisolone aceponate in 
paediatric and adult patients suffering from 
moderate-to-severe AD.74 Study medications were 
applied once daily twice a week (except one study 
of tacrolimus with application 3 times a week) 
over a period up to 16 weeks and 40 weeks for TCS 
and TCI, respectively. The data showed that the 
proactive treatment approach was more efficacious 
in prevention of flares during the treatment period 
but long-term safety data are lacking.74 The results 
suggested that for a patient with moderate-to-severe 
eczema and chronic relapsing lesions, maintenance 
treatment with topical anti-inflammatory therapy 
twice a week may be a better strategy to prevent AD 
flares and TCS may be more effective than TCIs.74 
Topical sodium cromoglicate
Sodium cromoglicate (SCG) has anti-allergic, anti-
itch, and anti-inflammatory properties. It has been 
used topically in the treatment of asthma, allergic 
rhinitis, and allergic conjunctivitis. Recently, the 
effect of a new formulation of 4% SCG cutaneous 
emulsions was evaluated as treatment for children 
with AD.75 A meta-analysis of three multicentre 
RCTs involving 490 children with AD and a mean age 
of 5.3 years compared the outcomes of application 
of SCG emulsion against vehicle over a 12-week 
period.75 There was significant improvement in 
SCORAD score within the treatment group and 4% 
SCG produced a more significant but clinically mild 
difference in SCORAD score of -2.82 (-5.36; -0.29), 
P=0.03.75 Another RCT of 208 children aged 2 to 
12 years over 12 weeks showed that 4% SCG was 
more effective in terms of greater improvement in 
SCORAD and SASSAD (Six Area, Six Sign Atopic 
Dermatitis) severity scores and reduced use of 
topical steroids during treatment periods.76 These 
results suggested that 4% SCG emulsion could be an 
effective treatment for children with AD. 
Antimicrobials and antiseptics
There is no doubt that Staphylococcus aureus is 
linked to AD and treatment with short-course oral 
antibiotics in infected AD is a common practice 
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despite the lack of supportive evidence.77,78 A 
systematic review included 26 short-term low-
quality studies of 1229 AD participants and 
compared various interventional strategies to 
reduce S aureus infection, including oral antibiotics, 
topical antibiotics, or topical anti-septics.79 The 
authors concluded that anti-staphylococcal 
strategies can reduce the amount of bacteria in skin 
but the clinical benefit, especially in non-infected 
AD, remains uncertain. Large-scale long-term 
good-quality studies are needed to study clinical 
outcomes and adverse effects. One study involved 
31 children (6 months to 17 years) with moderate-
to-severe AD and evidence of bacterial infection 
who were randomised to use diluted bleach bath of 
0.005% sodium hypochlorite twice per week plus 
nasal mupirocin 5 days per month for 3 months.80 
Bacteria count was reduced and there was significant 
improvement in mean eczema EASI (Eczema Area 
and Severity Index) scores compared with placebo 
at 1 month and 3 months.80 Recent guidelines have 
included diluted bleach bath and nasal mupirocin 
as a recommended treatment for patients with 
moderate-to-severe AD and clinical signs of 
secondary bacterial infection.30,34,40 
Antihistamines 
Relief of itch will help to break the ‘itch-scratch 
cycle’ in AD. Despite the widespread use of first- and 
second-generation H1 antihistamines in AD, there 
is no strong evidence that oral antihistamines are 
effective anti-pruritics.81 They are safe to use and 
their sedative effects, where present, may be useful 
to promote better sleep quality. 
Systemic immunomodulating therapy
In patients with moderate-to-severe eczema 
who fail to respond to topical therapy, systemic 
immunomodulating agents have been prescribed 
as off-label medications. The European Treatment 
of Severe Atopic Eczema in Children Taskforce 
conducted a survey on the use of systemic therapy 
across eight European countries.82 Overall, 343 
consultant physicians responded with 89.2% 
dermatologists: 71% would initiate systemic 
immunosuppression for children with severe 
atopic eczema. Cyclosporin A (CsA; 43.0%) was 
the most popular first-line drug followed by oral 
corticosteroids (30.7%) and azathioprine (AZA; 
21.7%); CsA (33.6%) and AZA (28.7%) were the two 
most commonly used as second-line medication, 
while methotrexate (MTX) was ranked as the most 
popular third-line drug (26.2%).82 Around half of 
the respondents (53.7%) replied that they routinely 
test and treat cutaneous infection prior to starting 
systemic treatment and 78.3% used penicillins 
as the first choice of antibiotics.82 Roekevisch 
et al83 recently published an updated systematic 
review based on Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) 
methodology, on the efficacy and safety of 12 systemic 
treatment interventions for moderate-to-severe AD. 
Overall, 34 RCTs were selected comprising a total 
of 1653 paediatric and adult patients. It concluded 
that CsA, AZA, and MTX could be recommended 
as systemic treatment for refractory AD. There were 
14 short-term and long-term studies on CsA that all 
demonstrated improvement in clinical outcomes, and 
short-term studies had the largest number of subjects 
for the strongest recommendations. Although the 
authors recommended CsA as a first-line therapy, 
AZA as second-line, and MTX as third-line systemic 
treatment for moderate-to-severe AD, there was 
a lack of data on direct comparison of the efficacy 
of these three agents.83 In addition, paediatric data 
were scant and the long-term safety profile of these 
medications in AD patients was uncertain. Clinicians 
should consider patient factors and potential risks 
when prescribing any one of the above systemic 
agents. Recommendations were not possible for 
other systemic treatment including mycophenolate 
mofetil, intravenous gamma globulin, montelukast, 
systemic calcineurin inhibitors, and systemic 
corticosteroids due to limited or poor-quality data. 
Systemic oral glucocorticosteroids were used for 
years but the high risk of flares after cessation of 
treatment and unfavourable risk-benefit profile 
limited their clinical use, especially in children. 
Cyclosporin A
Cyclosporin A inhibits activation of T cells and has 
been originally used to control graft rejection in 
transplant patients. With accumulating experience 
and data about its role in the treatment of severe 
AD, international guidelines recommend CsA as a 
systemic immune therapy to consider for chronic 
severe eczema in children and adults who have failed 
to respond to topical therapy.28,33,34 Five RCTs with 
146 participants compared CsA with placebo and 
revealed an improvement in clinical eczema severity 
scores by 53% to 95% after treatment from 10 days 
to 8 weeks.84 One study also showed a decrease in 
surface area of involvement.84 In a systematic review 
of 15 controlled and uncontrolled studies including 
602 patients, cyclosporin consistently decreased the 
severity of atopic eczema.83 Analysis of 12 studies 
found a dose-related response at 2-week treatment 
with a pooled mean decrease in disease severity 
of 22% (95% confidence interval [CI], 8-36%) with 
low-dose cyclosporin (<3 mg/kg) and 40% (95% 
CI, 29-51%) at dosages of ≥4 mg/kg. After 6 to 8 
weeks, the relative effectiveness was 55% (95% CI, 
48-62%).83 A few studies compared CsA with other 
agents and showed it to be more effective than oral 
prednisolone, intravenous immunoglobulin (Ig), and 
phototherapy.81 There were four open-label paediatric 
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and adult long-term studies for CsA of up to 12 
months showing sustained effects with continuous 
use.81 The potential side-effects of CsA in AD are 
similar to those in other conditions that require 
CsA therapy. They include infection, nephrotoxicity, 
hypertension, hypertrichosis, gingival hyperplasia, 
increased risks of skin cancer and lymphoma. Patients 
should have their blood pressure checked at every 
visit with renal and liver function tests, and blood 
cell counts performed every 2 weeks for the first 2 to 
3 months of treatment, then monthly thereafter. The 
usual dosage recommendations of CsA ranged from 
2.5 to 6 mg/kg/day although a higher initial starting 
dosage of 5 mg/kg/day demonstrated a more rapid 
response and adverse effects were not reported to be 
dose-related. Nonetheless on balance, it is advisable 
to start at a lower dose of 2.5 to 3 mg/kg/day and 
titrate stepwise to ascertain the lowest maintenance 
dose for control with serum creatinine within 25% 
of baseline.28,33 As the long-term safety profile and 
relapse rate of CsA use in AD patients, in particular 
paediatric patients, is uncertain, it may be more 
suitable as a short-term therapy. Concomitant use of 
other immunosuppressants or phototherapy is not 
recommended.
Azathioprine 
Azathioprine is a purine analogue with 
immunomodulating properties. Similar to 
CsA, it was initially developed in the 1960s for 
treatment of graft-versus-host disease. In the 
past 20 years evidence has accumulated for its 
use as a steroid-sparing agent in the treatment 
of severe recalcitrant AD. Two RCTs in 98 adult 
patients found better improvement in SASSAD 
score following AZA treatment for up to 12 weeks 
compared with placebo.83 A study comparing 
AZA with MTX showed similar improvement in 
symptom scores and quality of life after 12 weeks 
of treatment.83 Paediatric data were limited but 
a few observational studies showed promising 
results. A local retrospective study of 17 children 
and young adults showed improved SCORAD score 
at 3 months and 6 months of treatment.85 Dosage 
recommendations ranged from 1 to 3 mg/kg/day. 
Mild side-effects such as gastro-intestinal 
intolerance and headache are common. Serious side-
effects have been linked to genetic polymorphism of 
thiopurine methyltransferase (TPMT), an important 
enzyme in the metabolism of AZA. Individuals 
with homozygous TPMT mutations (low or absent 
TPMT activity) are prone to develop life-threatening 
myelosuppression while those with supra-normal 
TPMT activity may respond less well to treatment 
but could be at higher risk of hepatotoxicity.33 The 
dosing of AZA can also be guided by TPMT activity 
as patients with TPMT activity at the heterozygous 
range respond at the low dosage range with no 
increase in toxicity.86 Measurement of TPMT level 
before initiation of treatment with AZA is generally 
recommended and regular monitoring of blood cell 
counts and liver function tests is indicated for all 
patients during the course of treatment.28,33
Methotrexate
Methotrexate is a folic acid antagonist with T-cell 
suppression, approved for use in two dermatological 
conditions including psoriasis and advanced mycosis 
fungoides. A few small-scale retrospective studies 
showed that MTX was effective in the treatment 
of AD adult patients.33,83 There were only a few 
paediatric retrospective case series demonstrating 
that MTX treatment in AD was safe, effective, 
and well tolerated.33 Recently, El-Khalawany et al87 
published the first RCT study comparing low-dose 
MTX (7.5 mg/week) and CsA (2.5 mg/kg/week) 
in 40 Egyptian children with severe AD. At the 
end of 12 weeks, there was a similar reduction in 
mean SCORAD score for MTX and CsA. The study 
showed 20% to 30% of patients on MTX had minor 
adverse effects of anaemia, fatigue and diarrhoea, 
and 20% had abnormal liver but none had significant 
liver toxicity or other adverse effects that required 
adjustment in treatment. 
Phototherapy
Garritsen et al88 performed the first systematic 
review of phototherapy in AD patients using GRADE 
system. Nineteen RCT studies of various modalities 
of photo(chemo)therapies with treatment duration 
of 10 days to 40 weeks involving 905 participants 
(age range, 8-83 years) were included. Meta-
analysis could not be performed as most studies 
were small scale with wide heterogeneity in quality 
and methodology. The authors concluded that 
narrowband ultraviolet B (NB-UVB) and ultraviolet 
A1 (UVA1) seemed to be the most effective forms 
of phototherapy.88 Psoralen plus UVA (PUVA) 
was also an effective option but generally not the 
first choice due to its association with side-effects. 
Other treatment modalities including full-spectrum 
UVA, broadband UVB, and full-spectrum light 
therapy were considered less effective treatment. 
Most forms of phototherapy were mainly used for 
treatment of chronic lichenified forms of moderate-
to-severe AD, except for high-dose UVA1 that 
was also effective for treatment of acute flares.88 In 
general, long-term exposure to UV light increases 
the risk of skin cancer. One report highlighted 
an increased risk of non-melanoma skin cancer 
in children with psoriasis on PUVA treatment.33 
There are, however, no data about the long-term 
risk of developing cancer in children undergoing 
NB-UVB.89 Common reported side-effects included 
xerosis cutis, erythema, burning sensations, and skin 
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pigmentation. Ultraviolet A treatment, particularly 
with the addition of oral psoralen (PUVA), was 
more likely to be associated with side-effects of 
photosensitivity, cataract formation, folliculitis, 
and photo-onycholysis. Side-effects of oral psoralen 
include headache, nausea, vomiting, and, rarely, 
hepatotoxicity. Concomitant therapy with emollients 
and TCS may be used for control of acute flare and 
maintenance therapy but TCI should be avoided. In 
current guidelines, phototherapy is considered a safe 
and effective second-line treatment for moderate-
to-severe AD.28,33,34 Available evidence supports 
NB-UVB as the preferred treatment with moderate-
dose UVA1 as an alternative treatment, while high-
dose UVA1 may be considered in the acute phase. 
Clinical response to the type, dose, and duration of 
phototherapy varied widely and treatment regimens 
have to be individualised. 
Dietary interventions 
The relationship of food allergy with AD is 
complex.90,91 Immunoglobulin E sensitisation to 
food has been reported in about 40% to 90% of 
patients with moderate-to-severe AD, but positive 
skin prick testing and specific IgE levels have 
poor predictive value for immediate or delayed 
eczematous reactions.91,92 Dietary avoidance based 
on food-specific IgA or IgG testing is not efficacious 
in ameliorating disease severity.93 Food allergens 
trigger eczema exacerbations especially in infants 
and young children but there is a lack of evidence 
that food allergens cause AD. A systematic review 
of the effects in nine trials of an elimination diet on 
existing eczema showed that there was no evidence 
to support the use of egg-free or milk-free dietary 
exclusion for unselected AD patients and no benefit 
for elemental or food-restricted diet in general.94 An 
exclusion diet is more likely to be useful in patients 
with a clinical history of IgE-mediated allergic 
reactions and young patients with severe disease.94 
An elimination diet should not be continued if no 
improvement is observed after 3 to 4 weeks.92 
Allergen-specific immunotherapy
Administration of allergen-specific immunotherapy 
(ASIT) through giving repeated incremental 
subcutaneous (SCIT) or sublingual (SLIT) doses of 
allergen may induce immune tolerance in patients 
sensitised to allergens. In patients with AD, the best 
evidence for use of ASIT is with the house dust mite 
(HDM) allergen. In a systematic review, eight RCTs 
that comprised a total of 385 AD subjects sensitised 
to HDM were given ASIT: six studies used SCIT 
and two studies used SLIT for a treatment period 
of 4 to 36 months. It was found that ASIT had a 
significant positive effect on clinical outcome of 
AD.95 The effect was significant in subgroup analysis 
for long-term treatment longer than 1 year, severe 
AD and SCIT, but insignificant for children only and 
SLIT.95 Nonetheless with the limitations of small-
scale heterogeneous studies, it is not possible to 
make specific recommendations on the use of ASIT. 
Current evidence suggests that ASIT may be one of 
the treatment options in patients with severe AD 
sensitised to HDM.28,34 
Chinese herbal medicine 
The beneficial effects of Chinese herbal medicine 
(CHM) in children with AD have not been 
consistently demonstrated.96,97 Meta-analyses have 
been performed by Cochrane reviews and show no 
conclusive evidence that oral intake of most Chinese 
herbs or Chinese herbal formulae used in the 
included studies could improve eczema.96 Further, 
they could not find convincing evidence that topical 
application of CHM, used alone or in conjunction 
with oral administration of Chinese herbal formula, 
could reduce the severity of eczema in children or 
adults. Even though the included studies claimed that 
there were statistically significant differences in the 
outcome measures for the CHM treatment groups 
compared with the control groups, these claims 
could not be substantiated due to a low strength of 
evidence and high risk of bias.98
 In a series of studies and a RCT, Hon et 
al99-102 demonstrated that a PentaHerbs concoction 
improved quality of life in children with moderate-
to-severe eczema. Experts in the Cochrane reviews 
have suggested that well-designed, adequately 
powered trials are needed to evaluate the efficacy 
and safety of CHM for managing eczema.96,103 
Psychological and educational interventions
Psychological symptoms  of stress, anxiety, and 
depression are prevalent among eczema patients 
and correlate with quality-of-life impairment.104 
Psychological and educational interventions are 
complementary to other therapeutic approaches to 
help patients and carers to cope with this chronic 
condition. These interventions were reviewed 
systematically and recently updated by the Cochrane 
Skin Group in 2014.105 Ten studies were included 
with nine studies reviewing predominantly parent-
focused educational interventions and one focused 
on child-centred psychological interventions.105 
One large study of 992 subjects revealed that 
the study group who received age-appropriate 
group education in six standardised sessions had 
significant improvement in disease severity score and 
quality of life.105 Due to the heterogeneity of inter-
ventions and outcome, the authors concluded that 
it was impossible to draw definitive conclusions and 
there was a need for further research, in particular 
standalone psychological interventions. 
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Conclusion
Management of AD has remained challenging, 
often not because of the lack of effective treatment 
but of non-adherence and unrealistic expectations 
on the part of patients or their parents. Detailed 
evaluation of disease severity, treatment history, and 
its impact on patients’ and parents’ quality of life will 
determine the individual success of management for 
this complex atopic disease. 
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